Evidence map›Paper›PMID 27931251›Full record

ArticleAlzheimer's research & therapy2016

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.

Panagiotis Alexopoulos, Lukas Werle, Jennifer Roesler, Nathalie Thierjung, Lena Sophie Gleixner, Igor Yakushev, Nikolaos Laskaris, Stefan Wagenpfeil, Philippos Gourzis, Alexander Kurz and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Panagiotis AlexopoulosDepartment of Psychiatry, University Hospital of Rion, University of Patras, 26504, Rio, Patras, Greece. panos.alexopoulos@upatras.gr.
Lukas WerleMax Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804, München, Germany.
Jennifer RoeslerDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Nathalie ThierjungDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Lena Sophie GleixnerDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Igor YakushevDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Nikolaos LaskarisDepartment of Informatics, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Stefan WagenpfeilInstitute of Medical Biometrics, Epidemiology, and Medical Informatics (IMBEI), University of the Saarland, 66421, Homburg/Saar, Germany.
Philippos GourzisDepartment of Psychiatry, University Hospital of Rion, University of Patras, 26504, Rio, Patras, Greece.
Alexander KurzDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Robert PerneczkyDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Germany.
Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
CIHRNIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundAccording to new diagnostic guidelines for Alzheimer's disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF) biomarker constellations on the progression risk of MCI patients.

methodsA multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181 (p-Tau) and amyloid-beta 1-42 (Aβ

resultsPatients with all biomarkers positive for AD (N = 145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N = 111) had the lowest. The risk of patients with only abnormal p-Tau and/or t-Tau (N = 49) or with positive Aβ

conclusionsThe risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesApolipoproteins EBiomarkersCognitive DysfunctionCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedPeptide FragmentsProportional Hazards Modelstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoproteins EBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseCerebrospinal fluidMild cognitive impairmentPrognosis

Identifiers

PMID27931251
PMCPMC5146856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.